Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds

2 min read Original article ↗

But the drug, an antibody that attacks the protein amyloid, does not work as well in people with more advanced disease.

By

  1. Sara Reardon

    1. Sara Reardon is a freelance journalist based in Bozeman, Montana.

An experimental drug can slow progression of Alzheimer’s disease in those who start taking it when the disease is still in its early stages. The drug, a monoclonal antibody called donanemab, does not improve symptoms. But among people who started taking it at the earliest stages of Alzheimer’s, 47% had no disease progression on some measures after one year, compared with 29% who took a placebo.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Nature 619, 682-683 (2023)

doi: https://doi.org/10.1038/d41586-023-02321-1

Updates & Corrections

  • Update 17 July 2023: This story has been updated with additional comment from scientists not involved in the research.

References

Subjects

Latest on: